Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Chinese

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2022, Vol. 27 ›› Issue (6): 696-708.doi: 10.12092/j.issn.1009-2501.2022.06.014

Previous Articles     Next Articles

Research progress of microRNA in diagnosis and treatment of prostate cancer

DING Hao1, GAO Zhenhua2, ZHENG Yun1,3   

  1. 1Faculty of Information Engineering and Automation, Kunming University of Science and Technology, Kunming 650500, Yunnan, China; 2Department of Urology, The First Affiliated Hospital of Kunming Medical University, Kunming 650032, Yunnan, China; 3Institute of Primate Translational Medicine, Kunming University of Science and Technology, Kunming 650500, Yunnan, China
  • Received:2022-01-28 Revised:2022-05-10 Online:2022-06-26 Published:2022-07-08

Abstract: Prostate cancer (PCa) is an epithelial malignancy that occurs in the prostate tissue and is the second most common cancer in men after lung cancer, affecting millions of men worldwide. MicroRNA (miRNA) is a non-coding small RNA of length 20-22nt that regulates gene expression post-transcriptionally. miRNAs are involved in the regulation of almost all important biological life processes such as cell cycle progression, cell proliferation, cell apoptosis, and cell migration. Recently, more and more studies have shown that miRNAs are involved in the occurrence of various human tumors including PCa. This review summarizes the current research progress of PCA-related miRNAs, and analyzes the role of malregulated miRNAs in the pathogenesis, diagnosis and treatment of PCa. In addition, the role of miRNA in the diagnosis and treatment of castration-resistant prostate cancer (CRPC) is emphasized.

Key words: prostate cancer, miRNA, CRPC, biomarkers, regulation mechanism, treatment

CLC Number: